High-dose Enerzair Breezhaler further cuts asthma exacerbations
New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose
Read More
Tag: indacaterol acetate
Novartis banks EC approval for Enerzair Breezhaler
The product includes the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
Read More
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
